logo

Acelrx Pharmaceuticals Inc. (ACRX)



Trade ACRX now with
  Date
  Headline
5/19/2022 8:34:48 AM AcelRx Pharma Provides Update On Reduced FDA REMS Requirements Related To DSUVIA
5/16/2022 7:37:58 AM AcelRx Pharma Q1 Net Loss $8.7 Mln Or $0.06/shr Vs Loss $9.0 Mln Or $0.08/shr Prior Year
5/10/2022 8:40:12 AM AcelRx : Study Found That SST Lowered Opioid Dose Required By Patients In Post-anesthesia Care Unit
3/10/2022 4:03:25 PM AcelRx Pharma Q4 Loss/share $0.06 Vs. Loss $0.10 Year Ago
2/1/2022 8:32:58 AM AcelRx Announces Publication Of Data On Use Of Sufentanil Sublingual Tablet During Awake Plastic Surgery Procedures
1/27/2022 8:35:00 AM AcelRx Announces Publication Of Article Highlighting Utility Of Sufentanil Sublingual Tablet In Pain Medicine Procedures
1/12/2022 8:34:59 AM AcelRx Announces Publication Of Editorial By Internationally Recognized Leader In Opioid-Sparing Surgery
12/15/2021 8:41:42 AM ACRX:Data Shows Reduced Hospital Stay &Opioid Utilization With Use Of Sublingual Sufentanil In Joint Replacement Surgery
11/23/2021 5:11:22 PM AcelRx Pharmaceuticals Appoints Jill Broadfoot To Its Board Of Directors
11/15/2021 6:50:02 AM AcelRx Reports $14 Mln Registered Direct Common Stock And Warrant Offering
11/15/2021 6:04:06 AM AcelRx Pharma Q3 Loss Per Share $0.07; Announces Execution Of Definitive Merger Deal To Acquire Lowell Therapeutics
8/30/2021 8:35:15 AM AcelRx: Results Announced During Presentation On Effect Of Sufentanil Sublingual Tablet On Outpatient Plastic Surgery
8/16/2021 4:04:00 PM AcelRx Pharma Q2 Loss/share $0.08, Same As Last Year
7/14/2021 8:38:09 AM AcelRx Reaches Deal For DZUVEO In Europe And In-licensing Deal For Two Products In U.S.
6/17/2021 8:40:32 AM AcelRx Enters Agreement With FDA Addressing Warning Letter Received For DSUVIA Promotional Materials